• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inhaled corticosteroids: not just for asthma, but for COVID-19?

作者信息

Liew Felicity, Openshaw Peter J M

机构信息

National Heart and Lung Institute, Imperial College London Faculty of Medicine, London W2 1NY, UK.

Section of Respiratory Infection, Imperial College London Faculty of Medicine, London W2 1NY, UK.

出版信息

Lancet Respir Med. 2022 Jun;10(6):526-527. doi: 10.1016/S2213-2600(22)00053-4. Epub 2022 Apr 7.

DOI:10.1016/S2213-2600(22)00053-4
PMID:35397799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8989394/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07db/8989394/c6d60a8ac1c2/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07db/8989394/c6d60a8ac1c2/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07db/8989394/c6d60a8ac1c2/gr1_lrg.jpg

相似文献

1
Inhaled corticosteroids: not just for asthma, but for COVID-19?吸入性糖皮质激素：难道仅用于哮喘，不能用于治疗新型冠状病毒肺炎吗？
Lancet Respir Med. 2022 Jun;10(6):526-527. doi: 10.1016/S2213-2600(22)00053-4. Epub 2022 Apr 7.
2
What does potency actually mean for inhaled corticosteroids?吸入性糖皮质激素的效价究竟是什么意思？
J Asthma. 2005 Jul-Aug;42(6):409-17. doi: 10.1081/JAS-57878.
3
Factors influencing growth effects of inhaled corticosteroids in children.影响儿童吸入性糖皮质激素生长效应的因素。
J Allergy Clin Immunol. 2015 Dec;136(6):1711-1712.e2. doi: 10.1016/j.jaci.2015.09.039.
4
Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? No.在哮喘治疗中，是否应该使用抗白三烯疗法替代吸入性糖皮质激素？答案是否定的。
Am J Respir Crit Care Med. 1998 Dec;158(6):1699-701. doi: 10.1164/ajrccm.158.6.15861.
5
Inhaled corticosteroids versus anti-leukotrienes: a literature review on the clinical effects.吸入性糖皮质激素与抗白三烯药物：关于临床疗效的文献综述
Allergy. 1999;54 Suppl 50:43-6. doi: 10.1111/j.1398-9995.1999.tb05027.x.
6
Addressing patients' concerns over inhaled corticosteroids.解决患者对吸入性皮质类固醇的担忧。
Community Nurse. 2000 Dec;6(11):19-22.
7
Long COVID outcomes in an asthmatic cohort and its implications for asthma control.哮喘队列中的长期新冠病毒感染结局及其对哮喘控制的影响。
Respir Med. 2023 Feb;207:107092. doi: 10.1016/j.rmed.2022.107092. Epub 2022 Dec 16.
8
Long-term management of asthma in children: safety of inhaled corticosteroids.
J Allergy Clin Immunol. 2002 Nov;110(5 Suppl):S160-8.
9
Different effect of inhaled and systemic corticosteroids on the outcome of COVID-19 among patients with asthma.吸入性和全身性皮质类固醇对哮喘患者新冠病毒疾病（COVID-19）结局的不同影响。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2777-2778. doi: 10.1016/j.jaip.2022.06.051.
10
Inhaled corticosteroids for asthma: guidance is inconsistent.吸入性皮质类固醇治疗哮喘：指南并不一致。
BMJ. 2019 Dec 16;367:l6934. doi: 10.1136/bmj.l6934.

引用本文的文献

1
Bioinformatic analysis and preliminary validation of potential therapeutic targets for COVID-19 infection in asthma patients.生物信息学分析和初步验证哮喘患者 COVID-19 感染潜在治疗靶点。
Cell Commun Signal. 2022 Dec 27;20(1):201. doi: 10.1186/s12964-022-01010-2.
2
Inhaled corticosteroids for the treatment of COVID-19.吸入性皮质类固醇治疗 COVID-19。
Eur Respir Rev. 2022 Nov 29;31(166). doi: 10.1183/16000617.0099-2022. Print 2022 Dec 31.
3
Clinical benefits of inhaled ciclesonide for hospitalized patients with COVID-19 infection: a retrospective study.

本文引用的文献

1
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis.上呼吸道黏膜早期 Th2 炎症作为 COVID-19 重症的预测指标，以及早期吸入皮质类固醇治疗的调节作用：机制分析。
Lancet Respir Med. 2022 Jun;10(6):545-556. doi: 10.1016/S2213-2600(22)00002-9. Epub 2022 Apr 7.
2
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.一项评估莫努匹韦在 COVID-19 患者中的 2a 期临床试验显示，其可加速 SARS-CoV-2 RNA 清除并消除具有感染性的病毒。
Sci Transl Med. 2022 Jan 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430.
3
COVID-19 感染住院患者吸入环索奈德的临床获益：一项回顾性研究。
BMC Pulm Med. 2022 Sep 28;22(1):368. doi: 10.1186/s12890-022-02168-8.
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
在英国社区中有并发症高风险的人群中使用布地奈德吸入剂治疗 COVID-19（PRINCIPLE）：一项随机、对照、开放标签、适应性平台试验。
Lancet. 2021 Sep 4;398(10303):843-855. doi: 10.1016/S0140-6736(21)01744-X. Epub 2021 Aug 10.
4
Tackling COVID-19 with neutralizing monoclonal antibodies.用中和单克隆抗体应对 COVID-19。
Cell. 2021 Jun 10;184(12):3086-3108. doi: 10.1016/j.cell.2021.05.005. Epub 2021 May 26.
5
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.吸入用布地奈德治疗早期 COVID-19（STOIC）：一项 2 期、开放标签、随机对照试验。
Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.
6
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.COVID-19 住院患者伴有基础呼吸系统疾病的不良结局风险：一项全国性、多中心前瞻性队列研究，使用 ISARIC WHO 临床特征化方案 UK。
Lancet Respir Med. 2021 Jul;9(7):699-711. doi: 10.1016/S2213-2600(21)00013-8. Epub 2021 Mar 4.
7
Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection.呼吸道黏膜中性粒细胞炎症使 RSV 感染易于发生。
Science. 2020 Oct 9;370(6513). doi: 10.1126/science.aba9301.
8
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform.在使用 OpenSAFELY 平台的观察性队列研究中，接受吸入皮质类固醇治疗的慢性阻塞性肺疾病或哮喘患者发生 COVID-19 相关死亡的风险。
Lancet Respir Med. 2020 Nov;8(11):1106-1120. doi: 10.1016/S2213-2600(20)30415-X. Epub 2020 Sep 24.
9
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
10
Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009).大流行 A/H1N1 流感住院和预后不良的危险因素：英国第一波（2009 年 5 月-9 月）。
Thorax. 2010 Jul;65(7):645-51. doi: 10.1136/thx.2010.135210.